miRagen Therapeutics Inc Receives a Buy from Wedbush

By Austin Angelo

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on miRagen Therapeutics Inc (NASDAQ: MGEN). The company’s shares opened today at $9.10.

According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 7.5% and a 37.3% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Global Blood Therapeutics.

miRagen Therapeutics Inc has an analyst consensus of Strong Buy.

Based on miRagen Therapeutics Inc’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $718K and GAAP net loss of $7.31 million. In comparison, last year the company earned revenue of $874K and had a GAAP net loss of $2.51 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Signal Genetics, Inc. is a commercial stage, molecular diagnostic company. It provides innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. The company was founded in January 2010 and is headquartered in Carlsbad, CA.